Annovis BioANVS
NYSEPharmaceuticals
No cached AI snapshot yet for ANVS.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
7 employees34.53M shares outstandinglisted 2020-01-29
Next earnings ~May 5, 2026
About Annovis Bio
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Latest News
Showing market-wide stock news
Bitcoin retreats after crypto bill setback, Fed next
This BlackRock strategist opposes a Fed hike. Here are the funds she recommends.
Gold outlook hinges on Fed signals; metal could test $4,200: Kotak Sec
US Dollar: Higher yields and oil support – MUFG
Bond Investors Are on Edge. Here's Why Stock Investors Should Pay Attention.
Wall St futures edge higher in countdown to Fed decision
Related Stocksin Pharmaceuticals
Ready to see the live AI view on ANVS?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing ANVS side-by-side with live signals.